Medexus Announces Move to a Virtual Meeting for 2020 AGM and Equity Incentive Grants
August 24 2020 - 7:57PM
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”)
(TSXV: MDP, OTCQX: PDDPF) today announced that due to
public health restrictions related to the COVID-19 pandemic, its
annual general meeting (the “
Meeting”) will be
held virtually by live webcast.
Details of the Meeting
The Meeting will be held virtually via live
webcast at https://web.lumiagm.com/455381759 on Thursday, September
17, 2020 at 9:30 a.m. Eastern Time. Shareholders will have an
opportunity to participate at the annual general meeting online
regardless of their geographic location. The webcast will enable
registered shareholders and duly appointed proxyholders to listen
to the virtual meeting, ask questions and vote online, all in real
time, provided they are connected to the Internet and properly
follow the instructions contained on the website. Non-registered
shareholders holding common shares beneficially through an
intermediary who have not duly appointed themselves as proxyholders
may still attend the live webcast of the Meeting as guests, but
will not have the ability to vote virtually or ask questions.
The Company believes hosting a virtual meeting
is in the best interests of all stakeholders and the broader
community. Shareholders will not be able to attend the Meeting in
person.
The Meeting can be accessed through the
following link:
https://web.lumiagm.com/455381759 in your web
browserPassword: medexus2020 (case sensitive)If you have voting
rights, select “Login” and follow the instructions.If you do not
have voting rights, select “Guest” and fill in the form.
Further details can be found in the management
information circular (the “Circular”) and related
meeting materials which have been filed on the Company’s profile at
www.SEDAR.com and are available on the Company’s website.
The Company encourages all shareholders to
participate in the Meeting. Shareholders that are unable to attend
the Meeting are encouraged to complete the form of proxy or voting
instruction form previously mailed to them and return it within the
time frames indicated on such forms so that their vote is counted
at the Meeting.
Equity Incentive Grants
The Company also announced today that the board
of directors of the Company (the “Board”) has
approved the issuance, today, of an aggregate of 49,365 restricted
share units (“RSUs”) to its non-executive
directors under the Company’s 2018 omnibus equity incentive plan
(the “Plan”).
Each vested RSU entitles the holder to receive
one common share of the Company by delivering an exercise notice in
accordance with the Plan and the terms of the applicable award
agreement. For consistency with the initial grant of RSUs to the
Company’s directors in December 2018, the RSUs have been granted
with an effective date of December 19, 2019, and will vest in equal
amounts upon the first, second, third and fourth anniversaries of
such effective date. The decision to issue the RSUs was made
on the recommendation of the Compensation, Corporate Governance and
Nominating Committee of the Board as part of the Company’s overall
director compensation program.
About Medexus Pharmaceuticals
Inc.
Medexus is a leading specialty pharmaceutical
company with a strong North American commercial platform. The
Company’s vision is to provide the best healthcare products to
healthcare professionals and patients, through our core values of
Quality, Innovation, Customer Service and Teamwork. Medexus
Pharmaceuticals is focused on the therapeutic areas of auto-immune
disease, hematology and allergy. The Company’s leading products
are: Rasuvo™ and Metoject® , a unique formulation of methotrexate
(auto-pen and pre-filled syringe) designed to treat rheumatoid
arthritis and other auto-immune diseases; IXINITY®, an intravenous
recombinant factor IX therapeutic for use in patients 12 years of
age or older with Hemophilia B – a hereditary bleeding disorder
characterized by a deficiency of clotting factor IX in the blood,
which is necessary to control bleeding; and Rupall®, an innovative
prescription allergy medication with a unique mode of action.
For more information, please
contact:
Ken d’Entremont, Chief Executive OfficerMedexus
Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:
ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus
Pharmaceuticals Inc.Tel.: 514-762-2626 ext. 202E-mail:
roland.boivin@medexus.com
Investor Relations (U.S.):Crescendo
Communications, LLCTel: +1-212-671-1020Email:
mdp@crescendo-ir.com
Investor Relations (Canada):Frank CandidoDirect
Financial Strategies and Communication Inc.Tel: 514-969-5530E-mail:
frank.candido@medexus.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2023 to Jul 2024